PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine

被引:32
|
作者
Huang, Qingrui [1 ,4 ]
Li, Dongxia [1 ]
Kang, Aijun [3 ]
An, Wenqi [2 ]
Fan, Bei [2 ]
Ma, Xiaowei [2 ]
Ma, Guanghui [1 ]
Su, Zhiguo [1 ]
Hu, Tao [1 ]
机构
[1] Chinese Acad Sci, Inst Proc Engn, Natl Key Lab Biochem Engn, Beijing 100190, Peoples R China
[2] Hualan Biol Engn Inc, Xinxiang 453003, Henan Province, Peoples R China
[3] Peking Univ, Hlth Sci Ctr, Dept Lab Anim Sci, Beijing 100191, Peoples R China
[4] Univ Chinese Acad Sci, Beijing 100190, Peoples R China
关键词
Neisseria meningitidis; Conjugate vaccine; Spacer arm; Polyethylene glycol; Immunogenicity; IN-VIVO; PEGYLATION; THIOLATION; ANTIBODIES; SAFETY;
D O I
10.1016/j.jconrel.2013.03.008
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Neisseria meningitidis is a life-threatening pathogen that causes meningitis and other clinical manifestations. As a key virulence determinant, meningococcal capsular polysaccharide (PS) can be used to prevent meningococcal diseases. Conjugation of PS to carrier protein can significantly improve the immunogenicity of PS and induce memory response in infants and young children. However, the conjugate vaccine may suffer from steric shielding of antigenic PS epitopes by carrier protein. Here, a heterobifunctional polyethylene glycol (PEG) was used as a spacer arm to conjugate meningococcal group Y capsular PS with tetanus toxoid (TT). PEG can avoid self-crosslink of PS and increase the PS/TT ratio of the vaccine. Significant structural change in TT and PS was not observed upon conjugation. As compared to the vaccine without PEG, immunization with the vaccine using PEG as the spacer arm led to a 3.0-fold increase in the PS-specific IgG titers and a prolonged immune persistence. Paradoxically, PEG, a non-immunogenic hydrophilic polymer has been widely used to couple therapeutic protein for increasing its circulatory time and decreasing its immunogenicity. Presumably, PEG can fully decrease the steric shielding effect of TT on antigenic epitopes of PS and suppress the immunogenicity of TT. In addition, PEG can prolong the immune persistence of the conjugate vaccine and improve its ability to elicit cellular immunity. Thus, PEG can be used as a spacer arm to develop more effective PS conjugate vaccine for prevention of bacterial infection. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:382 / 389
页数:8
相关论文
共 50 条
  • [31] Safety and Immunogenicity of a Tetravalent Polysaccharide Vaccine Against Meningococcal Disease
    Shao, Pei-Lan
    Chang, Luan-Yin
    Hsieh, Szu-Min
    Chang, Shan-Chwen
    Pan, Sung-Ching
    Lu, Chun-Yi
    Hsieh, Yu-Chia
    Lee, Chin-Yun
    Dobbelaere, Kurt
    Boutriau, Dominique
    Tang, Haiwen
    Bock, Hans L.
    Huang, Li-Min
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (07) : 539 - 547
  • [32] Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults
    Kshirsagar, Nilima
    Mur, Naidu
    Thatte, Urmila
    Gogtay, Nithya
    Viviani, Simonetta
    Preziosi, Marie-Pierre
    Elie, Cheryl
    Findlow, Helen
    Carlone, George
    Borrow, Ray
    Parulekar, Varsha
    Plikaytis, Brian
    Kulkarni, Prasad
    Imbault, Nathalie
    LaForce, F. Marc
    [J]. VACCINE, 2007, 25 : A101 - A107
  • [33] An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine
    Chandramohan, Daniel
    Hodgson, Abraham
    Coleman, Paul
    Baiden, Rita
    Asante, Kwaku
    Awine, Elizabeth
    Owusu-Agyei, Seth
    Boutriau, Dominique
    Nelson, Christopher B.
    Greenwood, Brain
    [J]. VACCINE, 2007, 25 : A83 - A91
  • [34] REACTOGENICITY AND IMMUNOGENICITY OF A QUADRIVALENT COMBINED MENINGOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN
    LEPOW, ML
    BEELER, J
    RANDOLPH, M
    SAMUELSON, JS
    HANKINS, WA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (06): : 1033 - 1036
  • [35] Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelet donors
    Desjardins, Michael
    Cunningham, Phoebe
    Mitre, Xhoi
    Pierre, Djenane
    Montesano, Christina
    Woods, Tenaizus
    Oganezova, Karina
    Krauss, Jonathan H.
    Von, Salena S.
    Kupelian, John A.
    Li, Xiaofang
    Gothing, Jon A.
    Kleinjan, Jane A.
    Zhou, Guohai
    Piantadosi, Steven
    Sherman, Amy C.
    Walsh, Stephen R.
    Issa, Nicolas C.
    Kaufman, Richard M.
    Baden, Lindsey R.
    [J]. BLOOD, 2023, 142 (02) : 202 - 209
  • [36] Safety and immunogenicity of tetravalent conjugate meningococcal vaccine (TetraMenD) in toddlers
    Rennels, M
    King, J
    Papa, T
    Wubbel, L
    Froeschle, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1151 - 1151
  • [37] Development of a group A meningococcal conjugate vaccine, MenAfriVac™
    Frasch, Carl E.
    Preziosi, Marie-Pierre
    LaForce, F. Marc
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (06) : 715 - 724
  • [38] Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults
    Campbell, JD
    Edelman, R
    King, JC
    Papa, T
    Ryall, R
    Rennels, MB
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (12): : 1848 - 1851
  • [39] Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine
    Fu, Chuanxi
    Huang, Guihua
    Cui, Min
    Wang, Ming
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 138 - 139
  • [40] Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence
    Findlow, Jamie
    Knuf, Markus
    [J]. FUTURE MICROBIOLOGY, 2019, 14 (07) : 563 - 580